396 related articles for article (PubMed ID: 11192473)
1. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events.
Hatanaka T
Clin Pharmacokinet; 2000 Dec; 39(6):397-412. PubMed ID: 11192473
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.
Shitara Y; Sugiyama Y
Pharmacol Ther; 2006 Oct; 112(1):71-105. PubMed ID: 16714062
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics of pravastatin.
Quion JA; Jones PH
Clin Pharmacokinet; 1994 Aug; 27(2):94-103. PubMed ID: 7955780
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
Desager JP; Horsmans Y
Clin Pharmacokinet; 1996 Nov; 31(5):348-71. PubMed ID: 9118584
[TBL] [Abstract][Full Text] [Related]
6. Tissue-selective uptake of pravastatin in rats: contribution of a specific carrier-mediated uptake system.
Yamazaki M; Tokui T; Ishigami M; Sugiyama Y
Biopharm Drug Dispos; 1996 Dec; 17(9):775-89. PubMed ID: 8968530
[TBL] [Abstract][Full Text] [Related]
7. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update.
Schachter M
Fundam Clin Pharmacol; 2005 Feb; 19(1):117-25. PubMed ID: 15660968
[TBL] [Abstract][Full Text] [Related]
8. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.
Kivistö KT; Niemi M
Pharm Res; 2007 Feb; 24(2):239-47. PubMed ID: 17177112
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacokinetics of statins.
Reinoso RF; Sánchez Navarro A; García MJ; Prous JR
Methods Find Exp Clin Pharmacol; 2002 Nov; 24(9):593-613. PubMed ID: 12616706
[TBL] [Abstract][Full Text] [Related]
10. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver.
Jacobsen W; Kirchner G; Hallensleben K; Mancinelli L; Deters M; Hackbarth I; Benet LZ; Sewing KF; Christians U
Drug Metab Dispos; 1999 Feb; 27(2):173-9. PubMed ID: 9929499
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
Williams D; Feely J
Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
[TBL] [Abstract][Full Text] [Related]
12. Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin.
Hirano M; Maeda K; Hayashi H; Kusuhara H; Sugiyama Y
J Pharmacol Exp Ther; 2005 Aug; 314(2):876-82. PubMed ID: 15901796
[TBL] [Abstract][Full Text] [Related]
13. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
Jacobson TA
Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
[TBL] [Abstract][Full Text] [Related]
14. Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver.
Yamazaki M; Suzuki H; Hanano M; Tokui T; Komai T; Sugiyama Y
Am J Physiol; 1993 Jan; 264(1 Pt 1):G36-44. PubMed ID: 8430803
[TBL] [Abstract][Full Text] [Related]
15. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
Mazzu AL; Lasseter KC; Shamblen EC; Agarwal V; Lettieri J; Sundaresen P
Clin Pharmacol Ther; 2000 Oct; 68(4):391-400. PubMed ID: 11061579
[TBL] [Abstract][Full Text] [Related]
16. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
Saito M; Hirata-Koizumi M; Urano T; Miyake S; Hasegawa R
J Clin Pharm Ther; 2005 Feb; 30(1):21-37. PubMed ID: 15659001
[TBL] [Abstract][Full Text] [Related]
17. The role of hepatic transport and metabolism in the interactions between pravastatin or repaglinide and two rOatp inhibitors in rats.
Badolo L; Bundgaard C; Garmer M; Jensen B
Eur J Pharm Sci; 2013 Jul; 49(4):767-72. PubMed ID: 23648783
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics of statins.
García MJ; Reinoso RF; Sánchez Navarro A; Prous JR
Methods Find Exp Clin Pharmacol; 2003; 25(6):457-81. PubMed ID: 12949632
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics.
Yamazaki M; Suzuki H; Sugiyama Y
Pharm Res; 1996 Apr; 13(4):497-513. PubMed ID: 8710738
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic evaluation for tissue-selective inhibition of cholesterol synthesis by pravastatin.
Hatanaka T; Honda S; Sasaki S; Katayama K; Koizumi T
J Pharmacokinet Biopharm; 1998 Jun; 26(3):329-47. PubMed ID: 10098103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
